# Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

> **NCT03916185** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 67 (actual)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** RSV ΔNS2/Δ1313/I1314L Vaccine
- **BIOLOGICAL:** RSV 6120/ΔNS2/1030s Vaccine
- **BIOLOGICAL:** RSV 276 Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03916185
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-20
- **Primary completion:** 2024-01-22
- **Final completion:** 2024-04-25
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** The study closed to enrollment prior to fully accruing due to difficulties with slower than expected accrual.
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03916185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03916185, "Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03916185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*